Dried blood spot (DBS) have been used as an alternative to plasma to increase access to HIV viral load monitoring and early infant diagnosis. DBS has also been applied as a sample collection method to detect SARS-CoV-2 downstream. Recently, the FDA approved the Vibrant COVID-19 antibody chemiluminescence immunoassay. The intended use is for the qualitative detection and differentiation of IgM and IgG antibodies to SARS-CoV-2 in human serum on Whatman™ 903 Proteinsaver Card (a sample collection card) using finger stick blood specimen.
In this webinar, Dr. Zahidul Mondle will present on: